Please assess the completion status of the following clinical trial:

Trial Title: Iloperidone for Symptoms of Arousal in Post Traumatic Stress Disorder (PTSD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* PTSD diagnosis~Exclusion Criteria:~* Pregnancy~* Traumatic Brain Injury greater than mild~* Primary sleep disorder~* Caffeinism~* Active substance use disorder~* Active suicidal risk~* Antipsychotic medication, antibiotics, sedatives, some antihypertensive or antiarrhythmic medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Iloperidone / Placebo (Type: EXPERIMENTAL): During 1st treatment period subjects will receive iloperidone. During 2nd treatment period subjects will receive placebo.
- Placebo / Iloperidone (Type: EXPERIMENTAL): During 1st treatment period subjects will receive placebo. During 2nd treatment period subjects will receive Iloperidone.

Based on this trial design, predict the completion outcome and termination type (if applicable).